VANCOUVER, BC, April 30, 2026 (GLOBE NEWSWIRE) — VVT Med Inc. (TSXV: VVTM) (“VVT Med” or the “Company”), a developer of minimally invasive, non-thermal, non-tumescent (“NT-NT”) options for venous illness, is happy to announce the publication of a peer-reviewed scientific examine evaluating the short-term efficacy and security of its ScleroSafe(R) catheter-directed sclerotherapy system. The examine, authored by Dr. Aniruddha Sanjoy Bhuiyan and Dr. Meet Taral Sheth of the Departments of Vascular and Endovascular Surgical procedure and Basic Surgical procedure at Holy Spirit Hospital and Medical Analysis Centre in Mumbai, India, was revealed within the Indian Journal of Vascular and Endovascular Surgical procedure (2026;13:64-66), a peer-reviewed journal revealed by Wolters Kluwer Medknow.
The examine, titled “Efficacy and Safety of ScleroSafe Catheter-directed Sclerotherapy for Varicose Veins: A Prospective Observational Study” was revealed on-line lately, on The Indian Journal of Vascular and Endovascular Surgical procedure, which is the official publication of the Vascular Society of India and is listed with Wolters Kluwer Medknow.
The possible observational examine enrolled 30 sufferers handled between March 2025 and July 2025 for symptomatic major varicose veins at Holy Spirit Hospital and Medical Analysis Centre in Mumbai. Eligible sufferers had CEAP class C2 to C5 illness with duplex-confirmed reflux within the nice or small saphenous vein and no prior venous interventions on the handled limb. All procedures have been carried out underneath ultrasound steering by a single skilled vascular surgeon. Technical success was outlined as profitable cannulation, catheter development to the sapheno-femoral or saphenopopliteal junction, and uniform sclerosant supply with rapid vein wall contact confirmed on ultrasound.
Scientific ResultsThe examine reported the next outcomes:
Scientific success: Achieved in all 30 sufferers (100%).Vein occlusion price: 95% at day 30 and 92% at day 90.Symptom aid: Speedy postprocedure enchancment was reported for leg heaviness in 80% of sufferers, ache in 65%, and swelling in 40%, inside 24 hours of the process.Security profile: No circumstances of deep vein thrombosis, thrombophlebitis, pores and skin necrosis, nerve damage, or new pigmentation have been noticed all through the 90-day follow-up interval.
More Read
The authors concluded that ScleroSafe catheter-directed sclerotherapy achieved excessive early closure charges and important symptom enchancment, describing it as a secure, efficient, and reproducible non-thermal different for managing superficial venous reflux.
“The publication of this peer-reviewed study in an indexed, internationally recognized journal represents an important milestone for VVT Med,” mentioned Erez Tetro, Chief Govt Officer of VVT Med. “Independent clinical data generated by vascular surgeons in routine practice, and validated through a rigorous peer-review process, provides meaningful external support for the efficacy and safety profile we have observed across our global commercial deployments. We believe this publication strengthens the clinical evidence base for ScleroSafe and supports the growing adoption of our NT-NT approach by physicians worldwide.”
About VVT Med Inc. (VVTM) VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) options for the therapy of vein ailments, beginning with varicose veins. VVT is the one FDA-cleared, standalone firm providing NT-NT varicose vein therapy know-how. VVT’s FDA-cleared and CE-marked catheter-based applied sciences, ScleroSafe® and V-Block™, allow secure, office-based procedures with no anesthesia, no downtime, and minimal ache and unwanted effects. Addressing the widest vary of vein diameters, VVT’s options empower sufferers by treating each the medical and aesthetic facets of vein illness, whereas enabling physicians to ship efficient, environment friendly, and cost-saving remedies by way of proprietary, simultaneous sclerosant injection and blood aspiration. The Firm’s patented know-how portfolio consists of 55 patents from 14 patent households throughout 20 international locations, offering broad international mental property safety by way of 2038. For extra data, go to www.vvtmed.com.
More Read
Neither the TSX Enterprise Trade nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Trade) accepts duty for the adequacy or accuracy of this launch.
